Clinical Trials · NCT07843472
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 2,500
- Start date
- Sep 2026
- Locations
- 3 sites, United States
- Primary endpoint
- Percentage Change in Body Weight from Baseline